Teva acquires BioXcel’s BXCL501, under FDA review for at-home agitation use; Rumi Therapeutics gains an option on Enthorin’s Fragile X PDE2 inhibitor.
Biopharma dealmaking remained active through the third quarter of 2026. DealForma data published by J.P. Morgan show 113 mergers and acquisitions worth $138.9 billion year to date, including 32 deals worth $31.1 billion in the third quarter.1
Two deals announced this week fall at different stages of that market. Teva acquired a late-stage neuroscience candidate, BXCL501, and an approved product from BioXcel Therapeutics through a bankruptcy court sale,2 while Rumi Therapeutics took an option on a compound from Enthorin Therapeutics that it describes as ready for an investigational new drug application.3
Teva’s deal includes contingent payments, while Rumi did not disclose financial terms.2,3
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., has completed its acquisition of neuroscience assets from BioXcel Therapeutics, Inc., including worldwide rights to BXCL501, an investigational dexmedetomidine sublingual film under FDA review for at-home treatment of agitation in adults with schizophrenia or bipolar I or II disorder.2
“Business development plays an important role in accelerating our Pivot to Growth strategy by bringing targeted external innovation into Teva,” says Evan Lippman, executive vice president of business development at Teva. “BXCL501 is a strong strategic fit with our neuroscience portfolio and reflects our disciplined focus on differentiated, late-stage opportunities that address unmet patient needs and create long-term value for Teva’s shareholders.”2
Teva paid $57.5 million upfront and could owe up to $67.5 million in contingent payments, some tied to the timing of regulatory approval and others to sales milestones.2 The court-supervised sale proceeded under Section 363 of the U.S. Bankruptcy Code and did not include the acquisition of BioXcel itself.2
The assets also include IGALMI (dexmedetomidine), an FDA-approved sublingual film for the same conditions in a hospital setting.2
BioXcel’s quarterly filing states that the supplemental new drug application for at-home use was submitted Jan. 14, 2026, and that FDA set a Nov. 14 target action date, less than three weeks after Teva’s announcement.4 The company reported that the supporting Phase 3 trial was designed to assess safety and was not powered for efficacy, so its efficacy findings are exploratory.4
Teva, citing its own market research, says acute agitation affects 25% to 40% of patients with schizophrenia or bipolar disorder, and that acute treatment options remain limited outside healthcare settings.2
“Agitation can escalate quickly, which is why the ability to intervene early matters,” says Eric Hughes, M.D., Ph.D., executive vice president of global research and development and chief medical officer at Teva. “If approved, BXCL501 could give adults living with schizophrenia or bipolar I or II disorder the ability to treat agitation at home, closer to the moment symptoms emerge and before they could become more difficult to manage.”
Rumi Therapeutics, a drug development company within Rumi Scientific Holdings, has entered an option to license agreement with Enthorin Therapeutics for RTX-7340 (ENT-7340), an investigational phosphodiesterase 2 (PDE2) inhibitor for Fragile X syndrome.3 Financial terms were not disclosed.
Rumi describes the candidate as ready for an investigational new drug application and says the deal moves it toward clinical development.3
Fragile X syndrome is a genetic neurodevelopmental disorder caused by changes in the FMR1 gene that reduce or eliminate production of a protein important for brain development, and it is a leading inherited cause of intellectual disability.3 The program draws on preclinical Fragile X models, including human organoid studies from sister company Rumi Scientific.
Rumi says PDE2A activity is increased in animal models and that inhibiting it has improved dendritic spine maturation, synaptic plasticity, and social and cognitive endpoints.3 An independent 2019 study in Cerebral Cortex found a similar pattern: PDE2A activity was elevated in the brains of Fmr1-knockout mice, and inhibiting it restored dendritic spine maturity and corrected social and communicative deficits in mouse and rat models.5
Rumi says RTX-7340 studies in Fmr1-knockout mice showed correction of disease-associated electroencephalography abnormalities, which the company plans to use to select neurophysiological measures for clinical evaluation.3
“We are pleased to partner with Rumi Therapeutics to advance RTX-7340 toward clinical evaluation in Fragile X syndrome. Rumi Scientific’s human organoid capabilities complement the preclinical development work supporting the candidate and create an opportunity to deepen our understanding of its therapeutic potential. Together, we aim to translate that scientific foundation into a focused clinical development program,” says J. Guy Breitenbucher, PhD, managing partner and co-founder of Enthorin Therapeutics.
A clinician quoted in the release addresses the translational question.
“A central challenge in Fragile X drug development is connecting a treatment’s effects on disease biology with outcomes that matter to patients. Combining human organoid research with neurophysiological measures creates an opportunity to build that connection more deliberately. A PDE2 program developed around this framework could help us evaluate both whether the drug affects relevant brain function and whether those effects translate into clinical benefit,” says Craig Ericksson, director of the Fragile X Syndrome Research and Treatment Center at Cincinnati Children’s Hospital.
The evidence cited so far comes from animal models, and the release states that the candidate’s human safety and efficacy have not been established. Because the arrangement is an option rather than a completed license, the release does not state the conditions or timeline for exercising it.3
